Transforming
Cancer Care
Together
At DAVA Oncology, we are driven by our mission to make state-of-the-art cancer care accessible to oncologists and their patients. Our core values of empowerment, collaboration, and innovation guide our efforts in providing cutting-edge educational resources and organizing flagship summits. We believe that through education and collaboration, we can transform cancer care and improve patient outcomes.
Our Commitment to Cancer Care
At DAVA Oncology, we’re dedicated to advancing cancer care through education, collaboration, and innovative solutions for oncologists and their patients.
Explore Our Oncology Summits
Your registration for these summits will include the following
Networking with the oncology thought leaders and community oncologists
Opportunity to listen to over 60 KOLs on the latest updates on over 140 topic
Access to Slides, papers, and posters presented during the summit
4 Breakfasts, and 3 Lunches for attendees
Discounted hotel and airfare rates
Latest Updates
Stay informed about breakthroughs in cancer care.
Breakthroughs in Bladder Cancer: Key Highlights from ASCO GU 2025
Key Takeaways Trial Updates: Antibody-Drug Conjugates (ADCs): Future Outlook: 26 February 2025 ASCO GU 2025 Symposium was a pivotal event in the landscape of bladder
US FDA approves Amgen’s colorectal cancer therapy: Lumakras (Sotorasib) and Vectibix (Panitumumab) for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s combination therapy of Lumakras (sotorasib) and Vectibix (panitumumab) for treating metastatic colorectal cancer in patients
FDA Approval: Grafapex (Treosulfan) for Allogeneic Stem Cell Transplantation in adult and pediatric patients aged one year and older with AML or MDS
The FDA has approved Grafapex (treosulfan) in combination with fludarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric
FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer
Key Highlights: Clinical Trial Findings: DESTINY-Breast06 The FDA’s decision was based on results from the phase 3 DESTINY-Breast06 trial (NCT04494425), which compared T-DXd with chemotherapy
Tumor DNA in Blood: A New Predictor of Lung Cancer Outcomes
ctDNA testing predicts lung cancer relapse, enabling personalized treatment and better outcomes.
Revolutionizing Cancer Treatment: CAR-NK Cell Therapy Offers New Hope for B-Cell Lymphoma
CAR-NK therapy offers a safer, more accessible alternative to CAR-T, using off-the-shelf natural killer cells to revolutionize cancer treatment with reduced toxicity and promising results.
Empowering Oncologists with Innovative Solutions
At DAVA Oncology, we are committed to advancing cancer care by providing oncologists with cutting-edge knowledge and resources. Our flagship summits foster collaboration and dialogue among experts, addressing the challenges of cancer care and improving patient outcomes.